(Q42641336)

4 November 2017

title

Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study (English)

1 reference

mild cognitive impairment

4 November 2017

main subject

1 reference

based on heuristic

inferred from title

cognitive dysfunction

1 reference

2

1 reference

4 November 2017

Rachelle S Doody

1

1 reference

4 November 2017

Stephen Salloway

3

1 reference

4 November 2017

Yijun Sun

4

1 reference

4 November 2017

Robert Goldman

5

1 reference

4 November 2017

Yikang Xu

6

1 reference

4 November 2017

Jeff Gao

7

1 reference

4 November 2017

Anita K Murthy

8

1 reference

4 November 2017

language of work or name

English

0 references

publication date

30 November 2009

1 reference

American Journal of Alzheimer's Disease & Other Dementias

4 November 2017

published in

1 reference

4 November 2017

volume

25

1 reference

4 November 2017

issue

2

1 reference

4 November 2017

page(s)

155-159

1 reference

Mild cognitive impairment as a diagnostic entity

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Current concepts in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Mild cognitive impairment represents early-stage Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Is functional decline necessary for a diagnosis of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Safety and efficacy of galantamine in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317509352334

21 January 2018

Identifiers

DOI

10.1177/1533317509352334

1 reference

4 November 2017

1 reference